Explore the revolutionary potential of biotechnology and gene editing, alongside crucial ethical considerations and ...
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced a symposium presentation highlighting clinical data from an ...
Researchers at the University of Bayreuth and Forschungszentrum Jülich have demonstrated that specific light-sensitive ...
Vietnam Investment Review on MSN
Brii Bio phase 2b hepatitis B data from ENRICH and ENHANCE studies released
DURHAM, N.C. and BEIJING, July 3, 2026 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient ...
Scientists have developed Spudcell, an advanced synthetic cell capable of adapting to its environment and learning survival skills, marking a breakthrough in synthetic biology.
Immunomic Therapeutics begins patient dosing in phase 1 trial of ITI-9001 to treat Japanese cedar pollen allergy: Rockville, Maryland Monday, July 6, 2026, 11:00 Hrs [IST] Immunom ...
PAS-004 has been well-tolerated, with all treatment-related adverse events (TRAEs) being Grade 1 or 2, no observed cardiac or retinal treatment-related events, and low rates of rash and ...
End-of-treatment data from ENRICH demonstrated higher HBsAg loss rates, consistent with ENSURE Cohort 4, confirming the role of BRII-179 in priming immune responses for functional cure ...
Oversubscribed $225 million concurrent private investment in public equity ("PIPE") with available cash to the combined ...
The Food and Drug Administration authorized Gain Therapeutics' investigational new drug application for a Parkinson's disease treatment, clearing the way for the biotechnology company to launch a ...
Permeasis Therapeutics (“Permeasis”), a biotechnology company developing intracellular biologics enabled by its proprietary Membrane Translocation Domain (MTD) platform announced the publication of ...
Dose-optimization data from the Phase 1 study expected Q3 2026 to support Phase 2 proof-of-concept initiation in ADPKD in Q4 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results